Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection.
Algorithms
Calcium
/ analysis
Cardiovascular Agents
/ therapeutic use
Cardiovascular Diseases
/ diagnosis
Consensus
Coronary Vessels
/ diagnostic imaging
Diabetes Mellitus, Type 2
/ complications
Glucagon-Like Peptide-1 Receptor
/ agonists
Humans
Hypoglycemic Agents
/ therapeutic use
Mass Screening
Patient Selection
Protective Agents
/ therapeutic use
Risk Assessment
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Tomography, X-Ray Computed
Diabetes mellitus
GLP1 agonists
SGLT2 inhibitors
cardiovascular disease
macrovascular
complications
risk stratification
Journal
Current diabetes reviews
ISSN: 1875-6417
Titre abrégé: Curr Diabetes Rev
Pays: United Arab Emirates
ID NLM: 101253260
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
09
2019
revised:
10
12
2019
accepted:
26
12
2019
pubmed:
29
1
2020
medline:
25
9
2020
entrez:
29
1
2020
Statut:
ppublish
Résumé
Cardiovascular disease (CVD), the main macro vascular complication of type 2 diabetes (T2D), increases the risk of death significantly in patients with T2D. Most of the patients with T2D do not have obvious CVD symptoms. Due to the paucity of data, CVD screening in asymptomatic patients with T2D remains highly controversial. This has driven a panel of experts to establish a novel consensus on how to approach patients with T2D at high CVD risk. The panel formulated a stepwise algorithm by which patients with T2D undergo initial risk stratification into low, intermediate and high risk using the ASCVD calculator. In patients with intermediate risk, coronary artery calcium measurement is used to further stratify those patients into new low and high-risk categories. The panel recommends using standard diabetes care in low risk patients and using SGLT2 inhibitors and GLP1 agonists with cardio protective effect, on top of standard care, in high risk individuals.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiovascular disease (CVD), the main macro vascular complication of type 2 diabetes (T2D), increases the risk of death significantly in patients with T2D.
INTRODUCTION
BACKGROUND
Most of the patients with T2D do not have obvious CVD symptoms. Due to the paucity of data, CVD screening in asymptomatic patients with T2D remains highly controversial.
METHODS
METHODS
This has driven a panel of experts to establish a novel consensus on how to approach patients with T2D at high CVD risk. The panel formulated a stepwise algorithm by which patients with T2D undergo initial risk stratification into low, intermediate and high risk using the ASCVD calculator. In patients with intermediate risk, coronary artery calcium measurement is used to further stratify those patients into new low and high-risk categories.
RESULTS AND CONCLUSION
CONCLUSIONS
The panel recommends using standard diabetes care in low risk patients and using SGLT2 inhibitors and GLP1 agonists with cardio protective effect, on top of standard care, in high risk individuals.
Identifiants
pubmed: 31987023
pii: CDR-EPUB-103771
doi: 10.2174/1573399816666200120122929
doi:
Substances chimiques
Cardiovascular Agents
0
GLP1R protein, human
0
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Protective Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Calcium
SY7Q814VUP
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
869-873Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.